reviewed the progress of pharmacogenomics research on metformin

In recent years, the guidelines for the diagnosis and treatment of type 2 diabetes mellitus(T2DM) have been constantly updated, and the drug treatment strategies have become increasingly individualized. Guidelines for the Prevention and Treatment of Type 2 Diabetes in China(2017 Edition) was officially published in January 2018. The new guidelines further highlight the cornerstone role of metformin in the treatment of hypoglycemia. However, massive clinical studies have shown that metformin, as the preferred hypoglycemic drug, has significant individual differences in drug response. Analyzing the main reasons, scholars mostly think that genetic factors are responsible for it, and most of the related studies focus on the genomics of drug target proteins, drug metabolic enzymes and drug transporter proteins. Therefore, in order to enrich people's understanding of individual differences about metformin drug response, this article reviewed the research progress of metformin from the perspective of pharmacogenomics.